Skip to main content
. 2010 Aug 17;1(9):466–471. doi: 10.1021/ml100128h

Table 2. SAR Development of Compound 50 at R3.

graphic file with name ml-2010-00128h_0008.jpg
a

Values are means of duplicate experiments on two separate weightings. NS5B enzyme, replicon, and cytotoxicity assay protocols are described in the Supporting Information.

b

ND, not determined.

c

Dashed lines, anti-HCV replicon activity masked by overlapping cellular CC50.